The FDA has granted de novo approval for Invitae Corporation's Common Hereditary Cancers Panel, a diagnostic test that can detect genetic variants associated with an elevated risk of developing certain cancers. The test, which is the first to be granted FDA marketing authorization, evaluates DNA from a blood sample to identify variants in 47 genes. Invitae tested over 9,000 clinical samples to validate the test's performance, achieving over 99.0% accuracy. The approval also creates a new regulatory classification, allowing future tests of the same type to use the FDA's 510(k) premarket process. Invitae's shares are up 13.70%.